An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT07583563 · tracked via the Priya Life Science UK tracker

Sponsor

Camurus AB

Phase

Observational

Started

2026-06-05

Last updated

2026-08-12

Condition(s) studied

Acromegaly

Investigational drug(s) / intervention(s)

Octreotide subcutaneous depot

Octreotide subcutaneous depot: Commercially available octreotide subcutaneous depot treatment administered by participants for a maximum duration up to 2 years in the study

Study summary

The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Have started or will be starting treatment with octreotide SC depot for acromegaly Exclusion Criteria: * Have started or will be starting treatment with octreotide SC depot for other conditions not related to acromegaly * Currently taking part in an interventional clinical trial or is still within a 30-day washout period from the end of taking part in an interventional clinical trial.

Primary outcome measure(s)

Incidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information. — From enrollment to the end of treatment at 2 years

Trial sites (6)

Facility	City	Region	Status
Universitaetsklinikum Aachen	Aachen	Germany	Not Yet Recruiting
Universitaetsklinikum Leipzig	Leipzig	Germany	Recruiting
Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie	Magdeburg	Germany	Recruiting
Medicover Neuroendokrinologie MVZ	München	Germany	Not Yet Recruiting
Universitätsklinikum Würzburg	Würzburg	Germany	Recruiting
St James's University Hospital - Leeds Teaching Hospitals NHS Trust	Leeds	United Kingdom	Not Yet Recruiting

Other trials for the same condition

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07583563 on ClinicalTrials.gov ↗ ← All trials in the UK